Performance / Research index
Tesamorelin
Tesamorelin is an analogue of growth hormone-releasing factor. Its clinical literature includes studies of abdominal fat accumulation in people with HIV. The population and the type of tissue measured are central to interpreting these findings, rather than details that can be removed from a claim.
Names used in the literature: Tesamorelin · Tesamorelina
Read the evidence and its sources ↓That presentation is not part of this listing. Review the available options before adding a selection.
Tesamorelin 10 mg
- Presentation
- 10 mg
- Catalog reference
- PMX-TESA-10MG
Availability and documentation await confirmation. Listed quantities identify catalog presentations, not instructions for use.
Visceral and subcutaneous fat
The study published in 2007 evaluated tesamorelin in people with HIV and treatment-associated central fat accumulation. It distinguished visceral from subcutaneous adipose tissue. That separation prevents a change in one particular compartment from becoming a general claim about total body weight or every pattern of excess fat accumulation.
Sources: [1]
What the liver-fat trial added
A 2014 trial enrolled 50 people with HIV, antiretroviral treatment and abdominal fat accumulation. It evaluated visceral and liver fat over six months. Its size, population and duration limit interpretation: these findings do not establish prevention of cardiovascular events or a general rejuvenation effect in other groups of people.
Sources: [2]
A specific indication and formulations
The U.S. Egrifta WR label checked in 2026 concerns excess abdominal fat in adults with HIV and lipodystrophy, and excludes general weight-loss management. It also distinguishes non-substitutable formulations. That information belongs to the identified medicine; it does not establish equivalence of an individual tesamorelin presentation in this catalog.
Sources: [3]
Questions about this reference
Does reducing visceral fat mean reducing anyone’s body weight?
No. Visceral fat is a specific anatomical compartment. The reference trial took place in a particular clinical context; its findings do not automatically extend to general obesity or people outside that context.
Does evidence for Egrifta validate every tesamorelin vial?
No. The label describes an identified medicine and formulation. Sharing its molecule’s name does not demonstrate the catalog vial’s equivalence, quality or authorization, and does not establish marketing authorization in Mexico.
Sources and original reading
- Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
- EGRIFTA WR — tesamorelin prescribing information
Content updated: . How this content is prepared and checked.
Understand before comparing